SK11852001A3 - Deriváty epotiólonu, spôsoby ich výroby a ich farmaceutické použitie - Google Patents

Deriváty epotiólonu, spôsoby ich výroby a ich farmaceutické použitie Download PDF

Info

Publication number: SK11852001A3
Authority: SK; Slovakia
Prior art keywords: dihydroxy; dione; ethenyl; methyl; ethyl
Prior art date: 1999-02-18

Application number

SK1185-2001A

Other languages

English (en)

Slovak (sk)

Inventor

Ulrich Klar

Werner Skuballa

Bernd Buchmann

Wolfgang Schwede

Michael Schirner

Original Assignee

Schering Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-18

Filing date

2000-02-18

Publication date

2002-04-04

1999-02-18 Priority claimed from DE19908765A external-priority patent/DE19908765A1/de

1999-11-04 Priority claimed from DE19954230A external-priority patent/DE19954230A1/de

2000-02-18 Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft

2002-04-04 Publication of SK11852001A3 publication Critical patent/SK11852001A3/sk

Links

238000004519 manufacturing process Methods 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 335
-1 2-hydroxymethyl-4-thiazolyl radical Chemical class 0.000 claims description 212
229910052739 hydrogen Inorganic materials 0.000 claims description 82
239000001257 hydrogen Substances 0.000 claims description 73
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 50
LZWPOLSJFGLQCE-UHFFFAOYSA-N heptadecane-5,9-dione Chemical compound CCCCCCCCC(=O)CCCC(=O)CCCC LZWPOLSJFGLQCE-UHFFFAOYSA-N 0.000 claims description 39
125000000217 alkyl group Chemical group 0.000 claims description 36
GESONPPMDAXJEH-UHFFFAOYSA-N cyclohexadec-9-ene-1,5-dione Chemical compound O=C1CCCCCCC=CCCCC(=O)CCC1 GESONPPMDAXJEH-UHFFFAOYSA-N 0.000 claims description 30
125000003118 aryl group Chemical group 0.000 claims description 24
125000004430 oxygen atom Chemical group O* 0.000 claims description 23
150000003883 epothilone derivatives Chemical class 0.000 claims description 21
150000002431 hydrogen Chemical class 0.000 claims description 21
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 20
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
125000006239 protecting group Chemical group 0.000 claims description 19
125000003710 aryl alkyl group Chemical group 0.000 claims description 18
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 15
238000002360 preparation method Methods 0.000 claims description 15
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 15
229910052801 chlorine Inorganic materials 0.000 claims description 13
239000000460 chlorine Substances 0.000 claims description 11
229910052736 halogen Inorganic materials 0.000 claims description 11
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
229910052794 bromium Inorganic materials 0.000 claims description 10
229910052731 fluorine Inorganic materials 0.000 claims description 10
125000005843 halogen group Chemical group 0.000 claims description 10
125000001309 chloro group Chemical group Cl* 0.000 claims description 9
150000002367 halogens Chemical class 0.000 claims description 9
229910052740 iodine Inorganic materials 0.000 claims description 9
125000003545 alkoxy group Chemical group 0.000 claims description 8
125000001153 fluoro group Chemical group F* 0.000 claims description 8
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 7
FIULGFJIHJJXMT-UHFFFAOYSA-N [C]1[N]C=CC=C1 Chemical compound [C]1[N]C=CC=C1 FIULGFJIHJJXMT-UHFFFAOYSA-N 0.000 claims description 7
125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
229910002091 carbon monoxide Inorganic materials 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
239000000543 intermediate Substances 0.000 claims description 5
SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical group C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 claims description 5
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
125000002252 acyl group Chemical group 0.000 claims description 4
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 4
125000004093 cyano group Chemical group *C#N 0.000 claims description 4
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 4
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 4
125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims description 4
125000001960 7 membered carbocyclic group Chemical group 0.000 claims description 3
101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 claims description 3
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 3
125000003277 amino group Chemical group 0.000 claims description 3
MPQXHAGKBWFSNV-UHFFFAOYSA-N oxidophosphanium Chemical group [PH3]=O MPQXHAGKBWFSNV-UHFFFAOYSA-N 0.000 claims description 3
150000003254 radicals Chemical group 0.000 claims description 3
125000001424 substituent group Chemical group 0.000 claims description 3
239000000825 pharmaceutical preparation Substances 0.000 claims description 2
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 4
150000002483 hydrogen compounds Chemical class 0.000 claims 3
125000004429 atom Chemical group 0.000 claims 1
229940079593 drug Drugs 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
LFVXJYQAKCTHIF-UHFFFAOYSA-N hexadec-13-ene-2,6-dione Chemical compound CC(CCCC(CCCCCCC=CCC)=O)=O LFVXJYQAKCTHIF-UHFFFAOYSA-N 0.000 claims 1
230000001681 protective effect Effects 0.000 claims 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 180
239000000243 solution Substances 0.000 description 127
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 123
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 121
238000005481 NMR spectroscopy Methods 0.000 description 89
239000000203 mixture Substances 0.000 description 89
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 48
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 48
239000012230 colorless oil Substances 0.000 description 46
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 45
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 40
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 39
229940126062 Compound A Drugs 0.000 description 37
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 37
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 34
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 33
229910052938 sodium sulfate Inorganic materials 0.000 description 32
235000011152 sodium sulphate Nutrition 0.000 description 32
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 28
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 27
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
238000000746 purification Methods 0.000 description 27
239000012634 fragment Substances 0.000 description 24
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 22
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 22
239000011541 reaction mixture Substances 0.000 description 21
239000000741 silica gel Substances 0.000 description 20
229910002027 silica gel Inorganic materials 0.000 description 20
239000007983 Tris buffer Substances 0.000 description 18
239000012299 nitrogen atmosphere Substances 0.000 description 18
238000010626 work up procedure Methods 0.000 description 18
239000002904 solvent Substances 0.000 description 16
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 15
239000012074 organic phase Substances 0.000 description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
229910052786 argon Inorganic materials 0.000 description 14
238000004440 column chromatography Methods 0.000 description 14
239000003921 oil Substances 0.000 description 14
238000001914 filtration Methods 0.000 description 13
238000010898 silica gel chromatography Methods 0.000 description 13
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 12
HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 12
238000004587 chromatography analysis Methods 0.000 description 11
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 10
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 10
239000000706 filtrate Substances 0.000 description 10
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
238000005160 1H NMR spectroscopy Methods 0.000 description 9
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
239000012300 argon atmosphere Substances 0.000 description 9
125000004432 carbon atom Chemical group C* 0.000 description 9
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 9
239000000284 extract Substances 0.000 description 9
HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
229930013356 epothilone Natural products 0.000 description 8
238000002955 isolation Methods 0.000 description 8
239000007787 solid Substances 0.000 description 8
229930012538 Paclitaxel Natural products 0.000 description 7
230000000694 effects Effects 0.000 description 7
QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 7
229960001592 paclitaxel Drugs 0.000 description 7
239000000725 suspension Substances 0.000 description 7
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 7
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
239000002585 base Substances 0.000 description 6
SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 6
HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
238000000034 method Methods 0.000 description 6
238000012746 preparative thin layer chromatography Methods 0.000 description 6
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
238000001816 cooling Methods 0.000 description 5
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 5
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 5
239000012044 organic layer Substances 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
239000012312 sodium hydride Substances 0.000 description 5
229910000104 sodium hydride Inorganic materials 0.000 description 5
FHUDAMLDXFJHJE-UHFFFAOYSA-N 1,1,1-trifluoropropan-2-one Chemical compound CC(=O)C(F)(F)F FHUDAMLDXFJHJE-UHFFFAOYSA-N 0.000 description 4
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
150000001299 aldehydes Chemical class 0.000 description 4
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
239000012043 crude product Substances 0.000 description 4
BEFZAMRWPCMWFJ-UHFFFAOYSA-N desoxyepothilone A Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC=CCC1C(C)=CC1=CSC(C)=N1 BEFZAMRWPCMWFJ-UHFFFAOYSA-N 0.000 description 4
BEFZAMRWPCMWFJ-QJKGZULSSA-N epothilone C Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QJKGZULSSA-N 0.000 description 4
XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
239000011737 fluorine Substances 0.000 description 4
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
150000004714 phosphonium salts Chemical class 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
235000019345 sodium thiosulphate Nutrition 0.000 description 4
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
PRIGFEJKMMRJSF-UHFFFAOYSA-M 1-fluoro-2,4,6-trimethylpyridin-1-ium;trifluoromethanesulfonate Chemical compound [O-]S(=O)(=O)C(F)(F)F.CC1=CC(C)=[N+](F)C(C)=C1 PRIGFEJKMMRJSF-UHFFFAOYSA-M 0.000 description 3
OZGSEIVTQLXWRO-UHFFFAOYSA-N 2,4,6-trichlorobenzoyl chloride Chemical compound ClC(=O)C1=C(Cl)C=C(Cl)C=C1Cl OZGSEIVTQLXWRO-UHFFFAOYSA-N 0.000 description 3
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
206010006187 Breast cancer Diseases 0.000 description 3
208000026310 Breast neoplasm Diseases 0.000 description 3
HIXQZXFNYOHUCV-UHFFFAOYSA-N CC(C)(C)[Si](C)(C)OC(C(O)=O)CCCCCCCCCC=CCCC=C Chemical compound CC(C)(C)[Si](C)(C)OC(C(O)=O)CCCCCCCCCC=CCCC=C HIXQZXFNYOHUCV-UHFFFAOYSA-N 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
BEFZAMRWPCMWFJ-JRBBLYSQSA-N Epothilone C Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C BEFZAMRWPCMWFJ-JRBBLYSQSA-N 0.000 description 3
XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 3
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
239000002253 acid Substances 0.000 description 3
235000019270 ammonium chloride Nutrition 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 description 3
229940043279 diisopropylamine Drugs 0.000 description 3
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 3
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
230000012010 growth Effects 0.000 description 3
125000005842 heteroatom Chemical group 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
239000011630 iodine Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
239000005445 natural material Substances 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
239000000047 product Substances 0.000 description 3
ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
239000007858 starting material Substances 0.000 description 3
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
ZFZINNLZVIUQNB-KLLNTFDXSA-N (4s,5r)-3-[(z,3s)-4-fluoro-3-hydroxy-5-pyridin-2-ylpent-4-enoyl]-4-methyl-5-phenyl-1,3-oxazolidin-2-one Chemical compound F/C([C@@H](O)CC(=O)N1C(=O)O[C@@H]([C@@H]1C)C=1C=CC=CC=1)=C\C1=CC=CC=N1 ZFZINNLZVIUQNB-KLLNTFDXSA-N 0.000 description 2
MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 2
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
AEHWVNPVEUVPMT-UHFFFAOYSA-N 2-methyl-1,3-thiazole-4-carbaldehyde Chemical compound CC1=NC(C=O)=CS1 AEHWVNPVEUVPMT-UHFFFAOYSA-N 0.000 description 2
XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
229920000858 Cyclodextrin Polymers 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
RZKYEQDPDZUERB-UHFFFAOYSA-N Pindone Chemical group C1=CC=C2C(=O)C(C(=O)C(C)(C)C)C(=O)C2=C1 RZKYEQDPDZUERB-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
102000004243 Tubulin Human genes 0.000 description 2
108090000704 Tubulin Proteins 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
125000004423 acyloxy group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
150000001540 azides Chemical class 0.000 description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
201000008275 breast carcinoma Diseases 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 2
150000002084 enol ethers Chemical class 0.000 description 2
125000002587 enol group Chemical group 0.000 description 2
150000003887 epothilone D derivatives Chemical class 0.000 description 2
230000032050 esterification Effects 0.000 description 2
238000005886 esterification reaction Methods 0.000 description 2
238000006266 etherification reaction Methods 0.000 description 2
QWWPUBQHZFHZSF-UHFFFAOYSA-N ethyl 2-methyl-1,3-thiazole-4-carboxylate Chemical compound CCOC(=O)C1=CSC(C)=N1 QWWPUBQHZFHZSF-UHFFFAOYSA-N 0.000 description 2
239000006260 foam Substances 0.000 description 2
DJPJIMVUISFALP-UHFFFAOYSA-N heptadeca-12,16-dienoic acid Chemical compound OC(=O)CCCCCCCCCCC=CCCC=C DJPJIMVUISFALP-UHFFFAOYSA-N 0.000 description 2
125000001072 heteroaryl group Chemical group 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000002372 labelling Methods 0.000 description 2
HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
239000002547 new drug Substances 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000012071 phase Substances 0.000 description 2
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
125000004076 pyridyl group Chemical group 0.000 description 2
238000010791 quenching Methods 0.000 description 2
230000000171 quenching effect Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000007363 ring formation reaction Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 2
229960005314 suramin Drugs 0.000 description 2
125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000006257 total synthesis reaction Methods 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
XUNKPNYCNUKOAU-VXJRNSOOSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]a Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XUNKPNYCNUKOAU-VXJRNSOOSA-N 0.000 description 1
ZUQBAQVRAURMCL-DOMZBBRYSA-N (2s)-2-[[4-[2-[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioic acid Chemical compound C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZUQBAQVRAURMCL-DOMZBBRYSA-N 0.000 description 1
CLLFEJLEDNXZNR-UUOKFMHZSA-N (4ar,6r,7r,7as)-6-(6-amino-8-chloropurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Cl CLLFEJLEDNXZNR-UUOKFMHZSA-N 0.000 description 1
PQQFQURPXMYVCA-KWQFWETISA-N (4s,5r)-3-(2-bromoacetyl)-4-methyl-5-phenyl-1,3-oxazolidin-2-one Chemical compound O1C(=O)N(C(=O)CBr)[C@@H](C)[C@H]1C1=CC=CC=C1 PQQFQURPXMYVCA-KWQFWETISA-N 0.000 description 1
RPYJRCVJIZSSIW-ZHPNBBGOSA-N (4s,5r)-3-[(z,3r)-4-chloro-3-hydroxy-5-pyridin-2-ylpent-4-enoyl]-4-methyl-5-phenyl-1,3-oxazolidin-2-one Chemical compound Cl/C([C@H](O)CC(=O)N1C(=O)O[C@@H]([C@@H]1C)C=1C=CC=CC=1)=C\C1=CC=CC=N1 RPYJRCVJIZSSIW-ZHPNBBGOSA-N 0.000 description 1
DWGBOECXVWDEQP-LXASJJHUSA-N (4s,5r)-3-[(z,3s)-3-[tert-butyl(dimethyl)silyl]oxy-4-chloro-5-pyridin-2-ylpent-4-enoyl]-4-methyl-5-phenyl-1,3-oxazolidin-2-one Chemical compound Cl/C([C@@H](O[Si](C)(C)C(C)(C)C)CC(=O)N1C(=O)O[C@@H]([C@@H]1C)C=1C=CC=CC=1)=C\C1=CC=CC=N1 DWGBOECXVWDEQP-LXASJJHUSA-N 0.000 description 1
RPYJRCVJIZSSIW-KLLNTFDXSA-N (4s,5r)-3-[(z,3s)-4-chloro-3-hydroxy-5-pyridin-2-ylpent-4-enoyl]-4-methyl-5-phenyl-1,3-oxazolidin-2-one Chemical compound Cl/C([C@@H](O)CC(=O)N1C(=O)O[C@@H]([C@@H]1C)C=1C=CC=CC=1)=C\C1=CC=CC=N1 RPYJRCVJIZSSIW-KLLNTFDXSA-N 0.000 description 1
GCCVRCZMVYRDCO-KWQFWETISA-N (4s,5r)-3-acetyl-4-methyl-5-phenyl-1,3-oxazolidin-2-one Chemical compound O1C(=O)N(C(C)=O)[C@@H](C)[C@H]1C1=CC=CC=C1 GCCVRCZMVYRDCO-KWQFWETISA-N 0.000 description 1
125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
JWJGLIUKVUBWAW-KXFIGUGUSA-N (z)-2-chloro-3-(2-methyl-1,3-thiazol-4-yl)prop-2-en-1-ol Chemical compound CC1=NC(\C=C(/Cl)CO)=CS1 JWJGLIUKVUBWAW-KXFIGUGUSA-N 0.000 description 1
VEFCKGKBKIYHKO-KXFIGUGUSA-N (z)-2-chloro-3-(2-methyl-1,3-thiazol-4-yl)prop-2-enal Chemical compound CC1=NC(\C=C(/Cl)C=O)=CS1 VEFCKGKBKIYHKO-KXFIGUGUSA-N 0.000 description 1
FNUMEHGVESYHKX-ALCCZGGFSA-N (z)-2-chloro-3-pyridin-2-ylprop-2-en-1-ol Chemical compound OC\C(Cl)=C\C1=CC=CC=N1 FNUMEHGVESYHKX-ALCCZGGFSA-N 0.000 description 1
VLTUQPKHTVEAFO-ALCCZGGFSA-N (z)-2-chloro-3-pyridin-2-ylprop-2-enal Chemical compound O=CC(/Cl)=C/C1=CC=CC=N1 VLTUQPKHTVEAFO-ALCCZGGFSA-N 0.000 description 1
WKAOPSKQKLNWMU-KXFIGUGUSA-N (z)-2-fluoro-3-(2-methyl-1,3-thiazol-4-yl)prop-2-en-1-ol Chemical compound CC1=NC(\C=C(/F)CO)=CS1 WKAOPSKQKLNWMU-KXFIGUGUSA-N 0.000 description 1
NQDWIJCXVYPNJA-KXFIGUGUSA-N (z)-2-fluoro-3-(2-methyl-1,3-thiazol-4-yl)prop-2-enal Chemical compound CC1=NC(\C=C(/F)C=O)=CS1 NQDWIJCXVYPNJA-KXFIGUGUSA-N 0.000 description 1
ADOHBIBTKJWYCQ-ALCCZGGFSA-N (z)-2-fluoro-3-pyridin-2-ylprop-2-enal Chemical compound O=CC(/F)=C/C1=CC=CC=N1 ADOHBIBTKJWYCQ-ALCCZGGFSA-N 0.000 description 1
XVNSKFRSQKGCGX-XXYUJHKVSA-N (z,3s)-3-[tert-butyl(dimethyl)silyl]oxy-4-chloro-5-(2-methyl-1,3-thiazol-4-yl)pent-4-en-1-ol Chemical compound CC1=NC(\C=C(/Cl)[C@H](CCO)O[Si](C)(C)C(C)(C)C)=CS1 XVNSKFRSQKGCGX-XXYUJHKVSA-N 0.000 description 1
OILANPUENLZRAM-ZSMUJPCHSA-N (z,3s)-3-[tert-butyl(dimethyl)silyl]oxy-4-chloro-5-pyridin-2-ylpent-4-en-1-ol Chemical compound CC(C)(C)[Si](C)(C)O[C@@H](CCO)C(\Cl)=C\C1=CC=CC=N1 OILANPUENLZRAM-ZSMUJPCHSA-N 0.000 description 1
KRAMPGWMTXRREX-UHFFFAOYSA-N 1-[tert-butyl(dimethyl)silyl]oxy-16-fluoro-4,4,8,12-tetramethyl-17-pyridin-2-ylheptadeca-12,16-dien-5-one Chemical compound CC(C)(C)[Si](OCCCC(C(CCC(CCCC(=CCCC(=CC1=NC=CC=C1)F)C)C)=O)(C)C)(C)C KRAMPGWMTXRREX-UHFFFAOYSA-N 0.000 description 1
QHXXWZLTJOQQNF-NSHDSACASA-N 2-[(4s)-2,2-dimethyl-1,3-dioxan-4-yl]-2-methylhexan-3-one Chemical compound CCCC(=O)C(C)(C)[C@@H]1CCOC(C)(C)O1 QHXXWZLTJOQQNF-NSHDSACASA-N 0.000 description 1
IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
PMGINNPAPWFWMT-UHFFFAOYSA-N 2-chloro-2-phosphonoacetic acid Chemical compound OC(=O)C(Cl)P(O)(O)=O PMGINNPAPWFWMT-UHFFFAOYSA-N 0.000 description 1
OAWGYHQRRDKKPP-UHFFFAOYSA-N 2-fluoro-2-phosphonoacetic acid Chemical compound OC(=O)C(F)P(O)(O)=O OAWGYHQRRDKKPP-UHFFFAOYSA-N 0.000 description 1
CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
JBTFIWAQYSBSEZ-UHFFFAOYSA-N 3-pyridin-2-ylprop-2-yn-1-ol Chemical compound OCC#CC1=CC=CC=N1 JBTFIWAQYSBSEZ-UHFFFAOYSA-N 0.000 description 1
BTQAFTBKHVLPEV-UHFFFAOYSA-N 3h-naphtho[2,3-e]indazole Chemical class C1=CC=CC2=CC3=C4C=NNC4=CC=C3C=C21 BTQAFTBKHVLPEV-UHFFFAOYSA-N 0.000 description 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
KVXBRYKUCKGTAV-UHFFFAOYSA-N CC(C)(C)[Si](C)(C)OC(C=O)CCCCCCCCCC=CCCC=C Chemical compound CC(C)(C)[Si](C)(C)OC(C=O)CCCCCCCCCC=CCCC=C KVXBRYKUCKGTAV-UHFFFAOYSA-N 0.000 description 1
CAQDGUYKDGYMSV-UHFFFAOYSA-N CC(C)(C)[Si](C)(C)OC(O)CCCCCCCCCCC=CCCC=C Chemical compound CC(C)(C)[Si](C)(C)OC(O)CCCCCCCCCCC=CCCC=C CAQDGUYKDGYMSV-UHFFFAOYSA-N 0.000 description 1
XLTQUQYKLWQRJQ-UHFFFAOYSA-N C[Si](C(C)(C)C)(C)OC(CCC(=C)Cl)=O Chemical compound C[Si](C(C)(C)C)(C)OC(CCC(=C)Cl)=O XLTQUQYKLWQRJQ-UHFFFAOYSA-N 0.000 description 1
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229910021555 Chromium Chloride Inorganic materials 0.000 description 1
HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
229940127007 Compound 39 Drugs 0.000 description 1
229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
101710129448 Glucose-6-phosphate isomerase 2 Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241000575946 Ione Species 0.000 description 1
239000003810 Jones reagent Substances 0.000 description 1
229930194542 Keto Natural products 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
102000029749 Microtubule Human genes 0.000 description 1
108091022875 Microtubule Proteins 0.000 description 1
150000001204 N-oxides Chemical class 0.000 description 1
102000003923 Protein Kinase C Human genes 0.000 description 1
108090000315 Protein Kinase C Proteins 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
239000005708 Sodium hypochlorite Substances 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
229940123237 Taxane Drugs 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
ODEDPKNSRBCSDO-UHFFFAOYSA-N [2-(hexadecylsulfanylmethyl)-3-methoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCSCC(COC)COP([O-])(=O)OCC[N+](C)(C)C ODEDPKNSRBCSDO-UHFFFAOYSA-N 0.000 description 1
QQIRAVWVGBTHMJ-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;lithium Chemical compound [Li].C[Si](C)(C)N[Si](C)(C)C QQIRAVWVGBTHMJ-UHFFFAOYSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
BYRVKDUQDLJUBX-JJCDCTGGSA-N adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-JJCDCTGGSA-N 0.000 description 1
229950004955 adozelesin Drugs 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
230000002152 alkylating effect Effects 0.000 description 1
HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
229940043377 alpha-cyclodextrin Drugs 0.000 description 1
238000010640 amide synthesis reaction Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
238000011122 anti-angiogenic therapy Methods 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
230000003388 anti-hormonal effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000003418 antiprogestin Substances 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000005228 aryl sulfonate group Chemical group 0.000 description 1
125000004391 aryl sulfonyl group Chemical group 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
229960004853 betadex Drugs 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
KWAJGRXLJIZCBX-UHFFFAOYSA-M butanoate;tetrapropylazanium Chemical compound CCCC([O-])=O.CCC[N+](CCC)(CCC)CCC KWAJGRXLJIZCBX-UHFFFAOYSA-M 0.000 description 1
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
229940127093 camptothecin Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
150000001728 carbonyl compounds Chemical class 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229960001701 chloroform Drugs 0.000 description 1
QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
ARUGKOZUKWAXDS-SEWALLKFSA-N cicaprost Chemical compound C1\C(=C/COCC(O)=O)C[C@@H]2[C@@H](C#C[C@@H](O)[C@@H](C)CC#CCC)[C@H](O)C[C@@H]21 ARUGKOZUKWAXDS-SEWALLKFSA-N 0.000 description 1
229950000634 cicaprost Drugs 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
229960005537 combretastatin A-4 Drugs 0.000 description 1
HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 1
229940125878 compound 36 Drugs 0.000 description 1
JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
ONCCWDRMOZMNSM-FBCQKBJTSA-N compound Z Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 description 1
LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
229960000978 cyproterone acetate Drugs 0.000 description 1
UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
239000008298 dragée Substances 0.000 description 1
238000009509 drug development Methods 0.000 description 1
150000002066 eicosanoids Chemical class 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
150000003884 epothilone A derivatives Chemical class 0.000 description 1
150000003885 epothilone B derivatives Chemical class 0.000 description 1
SIHZWGODIRRSRA-ONEGZZNKSA-N erbstatin Chemical compound OC1=CC=C(O)C(\C=C\NC=O)=C1 SIHZWGODIRRSRA-ONEGZZNKSA-N 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
DTBXPWVORCYBEE-YWEYNIOJSA-N ethyl (z)-2-chloro-3-(2-methyl-1,3-thiazol-4-yl)prop-2-enoate Chemical compound CCOC(=O)C(\Cl)=C\C1=CSC(C)=N1 DTBXPWVORCYBEE-YWEYNIOJSA-N 0.000 description 1
GPPKCMDUCXNVOT-YWEYNIOJSA-N ethyl (z)-2-fluoro-3-(2-methyl-1,3-thiazol-4-yl)prop-2-enoate Chemical compound CCOC(=O)C(\F)=C\C1=CSC(C)=N1 GPPKCMDUCXNVOT-YWEYNIOJSA-N 0.000 description 1
BXYZAIZBRMSBJL-CLFYSBASSA-N ethyl (z)-2-fluoro-3-pyridin-2-ylprop-2-enoate Chemical compound CCOC(=O)C(\F)=C\C1=CC=CC=N1 BXYZAIZBRMSBJL-CLFYSBASSA-N 0.000 description 1
KHEBNWFMOHCHBA-IRVMHKCDSA-N ethyl (z,3s)-3-[tert-butyl(dimethyl)silyl]oxy-4-chloro-5-pyridin-2-ylpent-4-enoate Chemical compound CCOC(=O)C[C@H](O[Si](C)(C)C(C)(C)C)C(\Cl)=C\C1=CC=CC=N1 KHEBNWFMOHCHBA-IRVMHKCDSA-N 0.000 description 1
FVRDNHUXQQZQRL-MZLJFPOFSA-N ethyl (z,3s)-3-[tert-butyl(dimethyl)silyl]oxy-4-fluoro-5-(2-methyl-1,3-thiazol-4-yl)pent-4-enoate Chemical compound CCOC(=O)C[C@H](O[Si](C)(C)C(C)(C)C)C(\F)=C\C1=CSC(C)=N1 FVRDNHUXQQZQRL-MZLJFPOFSA-N 0.000 description 1
FVPISMANESAJQZ-UHFFFAOYSA-N ethyl 2-diethoxyphosphoryl-2-fluoroacetate Chemical compound CCOC(=O)C(F)P(=O)(OCC)OCC FVPISMANESAJQZ-UHFFFAOYSA-N 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
FQYYIPZPELSLDK-UHFFFAOYSA-N ethyl pyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC=CC=N1 FQYYIPZPELSLDK-UHFFFAOYSA-N 0.000 description 1
229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229940014144 folate Drugs 0.000 description 1
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000007306 functionalization reaction Methods 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
229940080345 gamma-cyclodextrin Drugs 0.000 description 1
239000000499 gel Substances 0.000 description 1
229940045109 genistein Drugs 0.000 description 1
TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
235000006539 genistein Nutrition 0.000 description 1
ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
AQQXEVUDIOWBPU-UHFFFAOYSA-N heptadeca-1,5-diene Chemical compound C=CCCC=CCCCCCCCCCCC AQQXEVUDIOWBPU-UHFFFAOYSA-N 0.000 description 1
OUSYGLDXUVXETB-UHFFFAOYSA-N heptadeca-12,16-dien-1-ol Chemical compound C(CCCCCCCCCCC=CCCC=C)O OUSYGLDXUVXETB-UHFFFAOYSA-N 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Natural products C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229950006905 ilmofosine Drugs 0.000 description 1
HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 1
229960002240 iloprost Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000005304 joining Methods 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
HTBVGZAVHBZXMS-UHFFFAOYSA-N lithium;tris[(2-methylpropan-2-yl)oxy]alumane Chemical compound [Li].[Al+3].CC(C)(C)[O-].CC(C)(C)[O-].CC(C)(C)[O-] HTBVGZAVHBZXMS-UHFFFAOYSA-N 0.000 description 1
229950000909 lometrexol Drugs 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
229940041033 macrolides Drugs 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
210000004688 microtubule Anatomy 0.000 description 1
VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
229960003248 mifepristone Drugs 0.000 description 1
229960005249 misoprostol Drugs 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
210000003887 myelocyte Anatomy 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000012038 nucleophile Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
AUONHKJOIZSQGR-UHFFFAOYSA-N oxophosphane Chemical compound P=O AUONHKJOIZSQGR-UHFFFAOYSA-N 0.000 description 1
125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
LEVJVKGPFAQPOI-UHFFFAOYSA-N phenylmethanone Chemical compound O=[C]C1=CC=CC=C1 LEVJVKGPFAQPOI-UHFFFAOYSA-N 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
150000003057 platinum Chemical class 0.000 description 1
239000002861 polymer material Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
239000012521 purified sample Substances 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
102000016914 ras Proteins Human genes 0.000 description 1
108010014186 ras Proteins Proteins 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
125000004469 siloxy group Chemical group [SiH3]O* 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
239000008259 solid foam Substances 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
229960001278 teniposide Drugs 0.000 description 1
PKRMIJLZLYPANW-XXYUJHKVSA-N tert-butyl-[(z,3s)-2-chloro-5-iodo-1-(2-methyl-1,3-thiazol-4-yl)pent-1-en-3-yl]oxy-dimethylsilane Chemical compound CC1=NC(\C=C(/Cl)[C@H](CCI)O[Si](C)(C)C(C)(C)C)=CS1 PKRMIJLZLYPANW-XXYUJHKVSA-N 0.000 description 1
IAUVGQANLCITQV-ZSMUJPCHSA-N tert-butyl-[(z,3s)-2-chloro-5-iodo-1-pyridin-2-ylpent-1-en-3-yl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[C@@H](CCI)C(\Cl)=C\C1=CC=CC=N1 IAUVGQANLCITQV-ZSMUJPCHSA-N 0.000 description 1
RXJNGNPHMDNUJA-XXYUJHKVSA-N tert-butyl-[(z,3s)-2-fluoro-5-iodo-1-(2-methyl-1,3-thiazol-4-yl)pent-1-en-3-yl]oxy-dimethylsilane Chemical compound CC1=NC(\C=C(/F)[C@H](CCI)O[Si](C)(C)C(C)(C)C)=CS1 RXJNGNPHMDNUJA-XXYUJHKVSA-N 0.000 description 1
BHXMMAXWAYULQE-ZSMUJPCHSA-N tert-butyl-[(z,3s)-2-fluoro-5-iodo-1-pyridin-2-ylpent-1-en-3-yl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[C@@H](CCI)C(\F)=C\C1=CC=CC=N1 BHXMMAXWAYULQE-ZSMUJPCHSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
239000010936 titanium Substances 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
229960000303 topotecan Drugs 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
WIOADUFWOUUQCV-UHFFFAOYSA-N triphenylphosphanium dichloride Chemical compound [Cl-].[Cl-].C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 WIOADUFWOUUQCV-UHFFFAOYSA-N 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
238000005292 vacuum distillation Methods 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
239000000341 volatile oil Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)

SK1185-2001A 1999-02-18 2000-02-18 Deriváty epotiólonu, spôsoby ich výroby a ich farmaceutické použitie SK11852001A3 (sk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE19908765A DE19908765A1 (de)	1999-02-18	1999-02-18	16-Halogen-Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19954230A DE19954230A1 (de)	1999-11-04	1999-11-04	16-Halogen-Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
PCT/EP2000/001333 WO2000049021A2 (de)	1999-02-18	2000-02-18	16-halogen-epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung

Publications (1)

Publication Number	Publication Date
SK11852001A3 true SK11852001A3 (sk)	2002-04-04

Family

ID=26052117

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1185-2001A SK11852001A3 (sk)	1999-02-18	2000-02-18	Deriváty epotiólonu, spôsoby ich výroby a ich farmaceutické použitie

Country Status (27)

Country	Link
US (3)	US6610736B1 (zh)
EP (1)	EP1150980B1 (zh)
JP (1)	JP2002537301A (zh)
KR (1)	KR100718616B1 (zh)
CN (1)	CN1209360C (zh)
AR (1)	AR022636A1 (zh)
AT (1)	ATE370946T1 (zh)
AU (1)	AU3156700A (zh)
BG (1)	BG105802A (zh)
BR (1)	BR0008331A (zh)
CA (1)	CA2361278A1 (zh)
CZ (1)	CZ20012951A3 (zh)
DE (1)	DE50014587D1 (zh)
EA (1)	EA009206B1 (zh)
EE (1)	EE200100431A (zh)
ES (1)	ES2291194T3 (zh)
HR (1)	HRP20010677A2 (zh)
HU (1)	HUP0105478A3 (zh)
IL (1)	IL144519A0 (zh)
MX (1)	MXPA01008328A (zh)
NO (1)	NO20014013L (zh)
NZ (1)	NZ513268A (zh)
PL (1)	PL349863A1 (zh)
SK (1)	SK11852001A3 (zh)
TW (1)	TWI285645B (zh)
WO (1)	WO2000049021A2 (zh)
YU (1)	YU59001A (zh)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0941227T5 (da)	1996-11-18	2009-10-05	Biotechnolog Forschung Gmbh	Epothilon D, dens fremstilling samt dens anvendelse som cytostatisk middel og som plantebeskyttelsesmiddel
US20050043376A1 (en) *	1996-12-03	2005-02-24	Danishefsky Samuel J.	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
CA2273083C (en)	1996-12-03	2012-09-18	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en)	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
US7407975B2 (en) *	1997-08-09	2008-08-05	Bayer Schering Pharma Ag	Epothilone derivatives, method for producing same and their pharmaceutical use
US6365749B1 (en)	1997-12-04	2002-04-02	Bristol-Myers Squibb Company	Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6380395B1 (en)	1998-04-21	2002-04-30	Bristol-Myers Squibb Company	12, 13-cyclopropane epothilone derivatives
US6498257B1 (en)	1998-04-21	2002-12-24	Bristol-Myers Squibb Company	2,3-olefinic epothilone derivatives
US6518421B1 (en) *	2000-03-20	2003-02-11	Bristol-Myers Squibb Company	Process for the preparation of epothilone analogs
DE10020899A1 (de) *	2000-04-20	2001-10-25	Schering Ag	9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
BRPI0206509B8 (pt)	2001-01-25	2021-05-25	R Pharm Us Operating Llc	processo para formular, para administração parenteral, um análogo de epotilona, preparação farmacêutica, processo para formar uma composição farmacêutica para administração parental, composição farmacêutica e uso de um análogo de epotilona na preparação de uma composição farmacêutica para o tratamento de câncer
MXPA03006485A (es)	2001-01-25	2003-09-22	Bristol Myers Squibb Co	Formulacion parenteral que contiene analogos de epotilona.
JP4633331B2 (ja) *	2001-01-25	2011-02-16	ブリストル−マイヤーズスクイブカンパニー	癌治療のためのエポチロン類似体の投与方法
NZ526871A (en) *	2001-01-25	2006-01-27	Bristol Myers Squibb Co	Pharmaceutical dosage forms of epothilones for oral administration
MXPA03007423A (es)	2001-02-20	2003-11-18	Bristol Myers Squibb Co	Derivados de epotilona para tratamiento de tumores refractarios.
EP1385529A4 (en)	2001-02-20	2007-05-09	Bristol Myers Squibb Co	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES
IL157443A0 (en)	2001-03-14	2004-03-28	Bristol Myers Squibb Co	Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
EP1392664A4 (en)	2001-06-01	2005-01-26	Bristol Myers Squibb Co	EPOTHILONE DERIVATIVES
WO2003026744A1 (en) *	2001-09-25	2003-04-03	Alcon, Inc.	The use of epothilones and analogs in conjunction with ophthalmic surgery
EP1340498A1 (en) *	2002-03-01	2003-09-03	Schering Aktiengesellschaft	Use of epothilones in the treatment of brain diseases associated with proliferative processes
AU2003218107A1 (en)	2002-03-12	2003-09-29	Bristol-Myers Squibb Company	C12-cyano epothilone derivatives
DK1483251T3 (da)	2002-03-12	2010-04-12	Bristol Myers Squibb Co	C3-cyano-epothilon-derivater
TW200403994A (en)	2002-04-04	2004-03-16	Bristol Myers Squibb Co	Oral administration of EPOTHILONES
TW200400191A (en)	2002-05-15	2004-01-01	Bristol Myers Squibb Co	Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
WO2003105828A1 (en)	2002-06-14	2003-12-24	Bristol-Myers Squibb Company	Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
PT1506203E (pt) *	2002-08-23	2007-04-30	Sloan Kettering Inst Cancer	Síntese de epotilonas, seus intermediários, seus análogos e suas utilizações
RU2462463C2 (ru) *	2002-08-23	2012-09-27	Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч	Синтез эпотилонов, их промежуточных продуктов, аналогов и их применения
US7649006B2 (en)	2002-08-23	2010-01-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
CN1705662B (zh)	2002-09-23	2011-07-06	布里斯托尔-迈尔斯斯奎布公司	埃坡霉素b的制备、分离和纯化的方法,及埃坡霉素b的x-射线晶体结构
EP1559447A1 (en)	2004-01-30	2005-08-03	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
MX2007005763A (es) *	2004-11-18	2007-07-20	Squibb Bristol Myers Co	Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma.
EP1824458A1 (en) *	2004-11-18	2007-08-29	Bristol-Myers Squibb Company	Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
EP1674098A1 (en)	2004-12-23	2006-06-28	Schering Aktiengesellschaft	Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
EP2634252B1 (en)	2005-02-11	2018-12-19	University of Southern California	Method of expressing proteins with disulfide bridges
CA2607940C (en)	2005-05-18	2009-12-15	Aegera Therapeutics Inc.	Bir domain binding compounds
US20070014978A1 (en) *	2005-07-18	2007-01-18	Anthony Poloso	Method of flame blocking and articles made therefrom
WO2007130501A2 (en) *	2006-05-01	2007-11-15	University Of Southern California	Combination therapy for treatment of cancer
SG10201407457UA (en)	2006-05-16	2014-12-30	Pharmascience Inc	Iap bir domain binding compounds
EP2065054A1 (en) *	2007-11-29	2009-06-03	Bayer Schering Pharma Aktiengesellschaft	Combinations comprising a prostaglandin and uses thereof
DE102007059752A1 (de)	2007-12-10	2009-06-18	Bayer Schering Pharma Aktiengesellschaft	Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (en)	2007-12-10	2009-06-17	Bayer Schering Pharma Aktiengesellschaft	Surface-modified nanoparticles
US8802394B2 (en)	2008-11-13	2014-08-12	Radu O. Minea	Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (en)	2009-01-27	2010-07-28	Bayer Schering Pharma Aktiengesellschaft	Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
KR20120140658A (ko)	2010-02-12	2012-12-31	파마사이언스 인크.	Ｉａｐｂｉｒ 도메인 결합 화합물
WO2013092998A1 (en)	2011-12-23	2013-06-27	Innate Pharma	Enzymatic conjugation of antibodies
WO2014009426A2 (en)	2012-07-13	2014-01-16	Innate Pharma	Screening of conjugated antibodies
EP3564259A3 (en)	2012-11-09	2020-02-12	Innate Pharma	Recognition tags for tgase-mediated conjugation
US10611824B2 (en)	2013-03-15	2020-04-07	Innate Pharma	Solid phase TGase-mediated conjugation of antibodies
EP3010547B1 (en)	2013-06-20	2021-04-21	Innate Pharma	Enzymatic conjugation of polypeptides
WO2014202775A1 (en)	2013-06-21	2014-12-24	Innate Pharma	Enzymatic conjugation of polypeptides
WO2019092148A1 (en)	2017-11-10	2019-05-16	Innate Pharma	Antibodies with functionalized glutamine residues
GB202309910D0 (en) *	2023-06-29	2023-08-16	Implexion Pharma Ab	Therpay

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2685521B2 (ja)	1988-08-05	1997-12-03	株式会社日立製作所	車両用換気装置
EP0353732A3 (de) *	1988-08-05	1991-11-06	Ciba-Geigy Ag	Neue Fluorolefine, Verfahren zu deren Herstellung und deren Verwendung
AU624034B2 (en) *	1989-12-27	1992-05-28	Monsanto Company	Substituted pyridine compounds
US6441186B1 (en) *	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
US7407975B2 (en) *	1997-08-09	2008-08-05	Bayer Schering Pharma Ag	Epothilone derivatives, method for producing same and their pharmaceutical use
AU5036999A (en) *	1998-06-30	2000-01-17	Schering Aktiengesellschaft	Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
DE10020517A1 (de) *	2000-04-19	2001-10-25	Schering Ag	Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung

2000
- 2000-02-18 DE DE50014587T patent/DE50014587D1/de not_active Expired - Fee Related
- 2000-02-18 CZ CZ20012951A patent/CZ20012951A3/cs unknown
- 2000-02-18 ES ES00909205T patent/ES2291194T3/es not_active Expired - Lifetime
- 2000-02-18 SK SK1185-2001A patent/SK11852001A3/sk unknown
- 2000-02-18 EA EA200100826A patent/EA009206B1/ru unknown
- 2000-02-18 AU AU31567/00A patent/AU3156700A/en not_active Abandoned
- 2000-02-18 PL PL00349863A patent/PL349863A1/xx not_active Application Discontinuation
- 2000-02-18 BR BR0008331-3A patent/BR0008331A/pt not_active Application Discontinuation
- 2000-02-18 YU YU59001A patent/YU59001A/sh unknown
- 2000-02-18 NZ NZ513268A patent/NZ513268A/en unknown
- 2000-02-18 EP EP00909205A patent/EP1150980B1/de not_active Expired - Lifetime
- 2000-02-18 HR HR20010677A patent/HRP20010677A2/hr not_active Application Discontinuation
- 2000-02-18 WO PCT/EP2000/001333 patent/WO2000049021A2/de not_active Ceased
- 2000-02-18 CA CA002361278A patent/CA2361278A1/en not_active Abandoned
- 2000-02-18 HU HU0105478A patent/HUP0105478A3/hu unknown
- 2000-02-18 JP JP2000599760A patent/JP2002537301A/ja active Pending
- 2000-02-18 AT AT00909205T patent/ATE370946T1/de not_active IP Right Cessation
- 2000-02-18 US US09/913,495 patent/US6610736B1/en not_active Expired - Fee Related
- 2000-02-18 EE EEP200100431A patent/EE200100431A/xx unknown
- 2000-02-18 CN CNB008039763A patent/CN1209360C/zh not_active Expired - Fee Related
- 2000-02-18 KR KR1020017010455A patent/KR100718616B1/ko not_active Expired - Fee Related
- 2000-02-18 IL IL14451900A patent/IL144519A0/xx unknown
- 2000-02-18 MX MXPA01008328A patent/MXPA01008328A/es active IP Right Grant
- 2000-02-21 AR ARP000100714A patent/AR022636A1/es unknown
- 2000-04-19 TW TW089102834A patent/TWI285645B/zh not_active IP Right Cessation
2001
- 2001-08-09 BG BG105802A patent/BG105802A/bg unknown
- 2001-08-17 NO NO20014013A patent/NO20014013L/no not_active Application Discontinuation
2003
- 2003-02-12 US US10/364,337 patent/US6930102B2/en not_active Expired - Fee Related
2005
- 2005-03-25 US US11/090,841 patent/US20050187270A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EE200100431A (et)	2002-12-16
DE50014587D1 (de)	2007-10-04
KR20010102215A (ko)	2001-11-15
AU3156700A (en)	2000-09-04
EP1150980A2 (de)	2001-11-07
HK1044945A1 (zh)	2002-11-08
NO20014013D0 (no)	2001-08-17
MXPA01008328A (es)	2002-06-04
IL144519A0 (en)	2002-05-23
YU59001A (sh)	2005-07-19
HUP0105478A2 (en)	2002-06-29
EA009206B1 (ru)	2007-12-28
TWI285645B (en)	2007-08-21
ES2291194T3 (es)	2008-03-01
CN1209360C (zh)	2005-07-06
ATE370946T1 (de)	2007-09-15
BR0008331A (pt)	2002-01-29
US6610736B1 (en)	2003-08-26
US20040014978A1 (en)	2004-01-22
WO2000049021A2 (de)	2000-08-24
BG105802A (bg)	2002-03-29
EA200100826A1 (ru)	2002-02-28
CA2361278A1 (en)	2000-08-24
JP2002537301A (ja)	2002-11-05
US6930102B2 (en)	2005-08-16
EP1150980B1 (de)	2007-08-22
HUP0105478A3 (en)	2002-08-28
US20050187270A1 (en)	2005-08-25
PL349863A1 (en)	2002-09-23
WO2000049021A3 (de)	2000-12-28
NO20014013L (no)	2001-10-18
KR100718616B1 (ko)	2007-05-16
AR022636A1 (es)	2002-09-04
NZ513268A (en)	2004-05-28
CZ20012951A3 (cs)	2001-11-14
HRP20010677A2 (en)	2005-06-30
CN1341115A (zh)	2002-03-20

Publication	Publication Date	Title
SK11852001A3 (sk)	2002-04-04	Deriváty epotiólonu, spôsoby ich výroby a ich farmaceutické použitie
KR100721488B1 (ko)	2007-05-23	6-알케닐-,6-알키닐- 및 6-에폭시-에포틸론 유도체, 그의제조 방법 및 제약 제제로서 그의 용도
US7407975B2 (en)	2008-08-05	Epothilone derivatives, method for producing same and their pharmaceutical use
RS59001B1 (sr)	2019-08-30	Miš sa zajedničkim lakim lancem
US20060040990A1 (en)	2006-02-23	Epothilone derivatives, process for their production, and their pharmaceutical use
AU4310300A (en)	2000-11-17	6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
EP1282618A2 (de)	2003-02-12	9-oxa-epothilon-derivate, verfahren zu deren herstellung sowie ihre verwendung in pharmazeutischen präparaten
ZA200107648B (en)	2003-01-07	16-Halogen-epothilone derivatives, method for producing them and their pharmaceutical use.
UA74542C2 (en)	2006-01-16	Epothilone 16-halogen derivatives, a pharmaceutical agent based thereon, intermediary compounds (variants)
DE10041470A1 (de)	2002-02-28	12,13-Cyclopropyl-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
AU2004200949A1 (en)	2004-04-01	16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
AU2004200948A1 (en)	2004-04-01	Epothilon derivatives, method for the production and the use thereof as pharmaceuticals
JP2009513498A (ja)	2009-04-02	エポチロンのｃ１−ｃ１５−フラグメント及びその誘導体の生成方法
DE19907480A1 (de)	2000-08-17	Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung